Deutsche Bank defends Gilead (GILD -1.6%) in the wake of the FDA's halting of Phase II clinical...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Deutsche Bank defends Gilead (GILD -1.6%) in the wake of the FDA's halting of Phase II clinical trials for Idenix's drug IDX184 over safety concerns, saying it's a buying opportunity. The firm says the concern is with non-quanosine nukes, and notes Gilead's GS 7977 is a pyrimidine based nuke. It reiterates its Buy rating with a $68 price target.